Emerging drugs on methicillin-resistant Staphylococcus aureus

Bibliography

• Klevens RM, Morrison MA, Nadle J, et al. Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin- resistant Staphylococcus aureus infections in the United States. JAMA 2007;298(15):1763-71
   PubMed Web of Science ®Google Scholar
• Available from: http://www.cdc.gov/mrsa/statistics/index.html
   Google Scholar
• Available from: http://www.ecdc.europa.eu/en/eaad/ documents/eaad-2011-summary-antimicrobial-resistance-data.pdf
   Google Scholar
• European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2007. Bilthoven, The Netherlands: EARSS; 2008. Available from: http://www.rivm.nl/earss/Images/EARSS% 202007 FINAL tcm61-55933.pdf [Accessed 17 March 2010]
   Google Scholar
• Chua K, Laurent F, Coombs G, et al. Antimicrobial resistance: not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 2011;52(1):99-114
   PubMed Web of Science ®Google Scholar
• Adam HJ, Allen VG, Currie A, et al. EMERGENT Working Group. Community-associated methicillin-resistant Staphylococcus aureus: prevalence in skin and soft tissue infections at emergency departments in the Greater Toronto Area and associated risk factors. CJEM 2009;11(5):439-46
   PubMedGoogle Scholar
• Pantosti A, Venditti M. What is MRSA? Eur Respir J 2009;34:1190-6
   PubMed Web of Science ®Google Scholar
• Orsi GB, Mastroianni CM, Giordano A, et al. Lack of community-associated MRSA in Rome. J Hosp Infect 2009;71:374-6
   PubMed Web of Science ®Google Scholar
• Dukic VM, Lauderdale DS, Wilder J, et al. Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis. PLoS ONE 2013;8(1):e52722; Epub 2013 Jan 2. Antimicrobial Agents and Chemotherapy. May 2013, Volume 57, Issue 5
   PubMed Web of Science ®Google Scholar
• Shurland S, Zhan M, Bradham DD, Roghmann MC. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007;28(3):273-9
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36(1):53-9
   PubMed Web of Science ®Google Scholar
• Shorr AF, Micek ST, Kollef MH. Inappropriate therapy for methicillin-resistant resource utilization and cost implications. Crit Care Med 2008;36:2335-40
   PubMed Web of Science ®Google Scholar
• Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6
   PubMed Web of Science ®Google Scholar
• Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the van A resistance gene. N Engl J Med 2003;348:1342-7
   PubMed Web of Science ®Google Scholar
• Weigel LM, Clewell DB, Gill SR, et al. Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 2003;302(5650):1569-71
   PubMed Web of Science ®Google Scholar
• Skrupky LP, Micek ST, Kollef MH. Bench-to-bedside review: understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit. Review. Crit Care 2009;13:222
   PubMedGoogle Scholar
• Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52(9):3315-20
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute updates antimicrobial susceptibility standard. Available from: http://www.laboratorytalk.com/services/-books-and-publishing/clsi-updates-antimicrobial-susceptibility-standard/389782.article
   Google Scholar
• Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005;52(2):113-22
   PubMed Web of Science ®Google Scholar
• Köck R, Becker K, Cookson B, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010;15(41):19688; Review. Erratum in: Euro Surveill.2010; 15(42). pii: 19694
   PubMedGoogle Scholar
• Elixhauser A, Steiner C. Infections with Methicillin-Resistant Staphylococcus Aureus (MRSA) in U.S. Hospitals, 1993–2005. Statistical Brief #35. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet] Agency for Health Care Policy and Research (US); Rockville (MD): 2006-2007
   Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Infectious diseases Society of America. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55
   PubMed Web of Science ®Google Scholar
• Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2007;45(Suppl 3):S184-90
   PubMedGoogle Scholar
• Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of panton-valentine leukocidin- positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005;128:2732-8
   PubMed Web of Science ®Google Scholar
• Reynolds PE. Structure, biochemistry, and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 1989;8:943-50
   PubMed Web of Science ®Google Scholar
• Nielsen EI, Cars O, Friberg LE. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PK/PD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 2011;55(10):4619-30
   PubMed Web of Science ®Google Scholar
• Knudsen JD, Fuursted K, Raber S, et al. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob Agents Chemother 2000;44:1247-54
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008;52(4):1330-6
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98
   PubMedGoogle Scholar
• Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 2009;53(8):3447-52
   PubMed Web of Science ®Google Scholar
• Roveta S, Marchese A, Schito GC. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp. Int J Antimicrob Agents 2008;31(4):321-8
   PubMed Web of Science ®Google Scholar
• Tally FP, DeBruin MF. Development of daptomycin for gram-positive infections. J Antimicrob Chemother 2000;46:523-6
   PubMed Web of Science ®Google Scholar
• Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50(10):3245-9
   PubMed Web of Science ®Google Scholar
• Patel JB, Jevitt LA, Hagerman J, et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis 2006;42(11):1652-3
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81
   PubMed Web of Science ®Google Scholar
• Fowler V Jr, Boucher H, Corey G, et al. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355(7):653-65
   PubMed Web of Science ®Google Scholar
• Martinez-Olondris P, Rigol M, Soy D, et al. Efficacy of linezolid compared to vancomycin in an experimental model of pneumonia induced by methicillin-resistant Staphylococcus aureus in ventilated pigs. Crit Care Med 2012;40(1):162-8
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54(5):621-9
   PubMed Web of Science ®Google Scholar
• Natalia Mendoza & Stephen K Tyring. Emerging drugs for complicated skin and skin-structure infections. Expert Opinion. 2010 Informa
   Google Scholar
• Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085249.htm
   Google Scholar
• Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005;56:923-9
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: non-inferiority of linezolid in a phase 3 study. Clin Infect Dis 2009;48(2):203-12
   PubMed Web of Science ®Google Scholar
• Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonine syndrome. Pharmacotherapy 2007;27:1189-97
   PubMed Web of Science ®Google Scholar
• Hentschke M, Saager B, Horstkotte M, et al. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection 2008;36:85-7
   PubMed Web of Science ®Google Scholar
• Sanchez Garcia M, De la Torre MA, Morales G, et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260-4
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54(5):621-9
   PubMed Web of Science ®Google Scholar
• Welte T, Pletz MW. Antimicrobial treatment of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents 2010;36(5):391-400; Review
   PubMed Web of Science ®Google Scholar
• Baudoux P, Lemaire S, Denis O, et al. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes. J Antimicrob Chemother 2010;65(6):1228-36
   PubMed Web of Science ®Google Scholar
• Deshpande LM, Fritsche TR, Moet GJ, et al. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58(2):163-70
   PubMed Web of Science ®Google Scholar
• Ramirez P, Fernandez-Barat L, Torres A. New therapy options for MRSA with respiratory infection/pneumonia. Curr Opin Infect Dis 2012;25:159-65
   PubMed Web of Science ®Google Scholar
• Perez F, Salata RA, Bonomo RA. Current and novel antibiotics against resistant gram-positive bacteria. Infect Drug Resist 2008;1:27-44
   PubMedGoogle Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
   PubMed Web of Science ®Google Scholar
• Vouillamoz J, Moreillon P, Giddey M, Entenza JM. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. J Antimicrob Chemother 2008;61(2):371-4
   PubMed Web of Science ®Google Scholar
• Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on non-inferiority trials. Clin Infect Dis 2012;54(12):1699-709
   PubMed Web of Science ®Google Scholar
• Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/ucm 228387.htm
   Google Scholar
• Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/ cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68(2):140-51
   PubMed Web of Science ®Google Scholar
• Bassetti M, Mikulska M, Righi E, et al. The role of telavancin in the treatment of MRSA infections in hospital. Expert Opin Investig Drugs 2009;18(4):521-9
   PubMed Web of Science ®Google Scholar
• Saravolatz LD, Pawlak J, Johnson LB. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2007;60(2):406-9
   PubMed Web of Science ®Google Scholar
• Liapikou A, Fernandez L, Torres A. Telavancin in the treatment of nosocomial pneumonia: review of the clinical evidence. Clin Investig 2012;2(9):939-48
   Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, Graham DR, Wilson SE, et al. Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46(11):1683-93
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001240/WC500106519.pdf
   Google Scholar
• Sader HS, Fritsche TR, Jones RN. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008;52(3):1153-5
   PubMed Web of Science ®Google Scholar
• Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52:3398-407
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-16
   PubMed Web of Science ®Google Scholar
• Forest Laboratories, Inc. Forest Laboratories announces positive top-line data from two pivotal phase III trials of ceftaroline for the treatment of community-acquired bacterial pneumonia (CABP) requiring hospitalization [press release]. 2009. New York, NY: Forest Laboratories, Inc. Available from: http:/www.frx.com/news/PressRelease.aspx?ID=1300673 [Accessed 19 March 2010]
   Google Scholar
• Available from: http://ecdc.europa.eu/en/eaad/Documents/EARS-Net-summary-antibiotic-resistance.pdf
   Google Scholar
• MRSA Surveillance. Centers for Disease Control and Prevention. April 8, 2011
   Google Scholar
• Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44
   PubMed Web of Science ®Google Scholar
• Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22(2):99-104
   PubMed Web of Science ®Google Scholar
• Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36(5):592-8
   PubMed Web of Science ®Google Scholar
• Mishra NN, McKinnell J, Yeaman MR, et al. In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011;55(9):4012-18
   PubMed Web of Science ®Google Scholar
• Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005;26:442-8
   PubMed Web of Science ®Google Scholar
• Schuerholz T, Dömming S, Hornef M, et al. Bacterial cell wall compounds as promising targets of antimicrobial agents II. Immunological and clinical aspects. Curr Drug Targets 2012;13(9):1131-7
   PubMed Web of Science ®Google Scholar
• Oku Y, Kurokawa K, Matsuo M, et al. Pleiotropic roles of polyglycerolphosphate synthase of lipoteichoic acid in growth of Staphylococcus aureus cells. J Bacteriol 2009;191:141-51
   PubMed Web of Science ®Google Scholar
• Gründling A, Schneewind O. Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureus. Proc Natl Acad Sci USA 2007;104(20):8478-83
   PubMed Web of Science ®Google Scholar
• Parsons JB, Frank MW, Subramanian C, et al. Metabolic basis for the differential susceptibility of gram-positive pathogens to fatty acid synthesis inhibitors. PNAS 2011;108(37):15379
   Google Scholar
• Brinster S, Lamberet G, Staels B, et al. Type II fatty acid synthesis is not a suitable antibiotic target for gram-positive pathogens. Nature 2009;458:83-6
   PubMed Web of Science ®Google Scholar
• Balemans W, Lounis N, Gilissen R, et al. Essentiality of FASII pathway for Staphylococcus aureus. Nature 2010;463(7279):E3
   PubMed Web of Science ®Google Scholar
• Capparelli R, Parlato M, Borriello G, et al. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 2007;51:2765-73
   PubMed Web of Science ®Google Scholar
• Matsuzaki S, Yasuda M, Nishikawa H, et al. Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 2003;187:613-24
   PubMed Web of Science ®Google Scholar
• Wills QF, Kerrigan C, Soothill JS. Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 2005;49:1220-1
   PubMed Web of Science ®Google Scholar
• Barczak AK, Hung DT. Productive steps toward an antimicrobial targeting virulence. Curr Opin Microbiol 2009;12:490-6
   PubMed Web of Science ®Google Scholar
• Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol 2005;3:948-58
   PubMed Web of Science ®Google Scholar
• Yuan Z, Trias J, White RJ. Deformylase as a novel antibacterial target. Drug Discov Today 2001;6(18):954-61
   PubMed Web of Science ®Google Scholar
• O'Dwyer K, Hackel M, Hightower S, et al. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob Agents Chemother 2013;57(5):2333-42
   PubMed Web of Science ®Google Scholar
• Giannakaki V, Miyakis S. Novel antimicrobial agents against multi-drug-resistant gram- positive bacteria: an overview. Recent Pat Antiinfect Drug Discov 2012;7(3):182-8
   PubMedGoogle Scholar
• In Vitro Evaluation of PTK 0796 Activity Tested against Staphylococcus aureus, Including Hospital- and Community-Associated MRSA Strains from the USA and Europe, Poster E-1569
   Google Scholar
• Hait H, Arbeit R, Molnar D, et al. PTK 0796 completed a randomized, evaluator-blinded >200 patient phase 2 complicated skin and skin structure infection (cSSSI) clinical study with IV and oral step-down therapy compared to Zyvox. Paratek; Boston: 2007
   Google Scholar
• Page MG. Anti-MRSA b-lactams in development. Curr Opin Pharmacol 2006;6:480-5
   PubMed Web of Science ®Google Scholar
• Available from: http://ir.tphase.com/releasedetail.cfm?ReleaseID= 747618
   Google Scholar
• Available from: http://tphase.com/files/L11647a%20Phase%202%20study%2030%20August%202012_Final%2012Sep.pdf
   Google Scholar
• Sader HS, Fritsche TR, Jones RN. Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates. Antimicrob Agents Chemother 2009;53(5):2171-5
   PubMed Web of Science ®Google Scholar
• Kohlhoff SA, Sharma R. Iclaprim. Expert Opin Investig Drugs 2007;16:1441-8
   PubMed Web of Science ®Google Scholar
• Krievins D, Brandt R, Hawser S, et al. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother 2009;53(7):2834-40
   PubMed Web of Science ®Google Scholar
• Sincak CA, Schmidt JM. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections. Ann Pharmacother 2009;43(6):1107-14
   PubMed Web of Science ®Google Scholar
• Leighton A, Dankner W, Stevens D, et al. Safety of iclaprim in complicated skin and skin structure infections: ASSIST-1 results (1104). Abstracts of the 45th Annual Meeting of Infectious Disease Society of America; San Diego, CA; 2007
   Google Scholar
• Available from: www.acinopharma.com/html//uploads/media/ACINO_Iclaprim_EN_20101220_Q45STpm.pdf
   Google Scholar
• Politano AD, Sawyer RG. NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. Curr Opin Investig Drugs 2010;11(2):225-36
   PubMed Web of Science ®Google Scholar
• McGhee P, Lowther J, Bryskier A, Appelbaum PC. Antistaphylococcal Activity of NXL103 (linopristine-floprisitne) Compared to Other Agents. 48th ICAAC/46th IDSA; Washington; 2008
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT00653172?term=NXL103&rank=1
   Google Scholar
• Prokocimer PP, Bien P, DeAnda C, et al. In vitro activity and microbiological efficacy of tedizolid (TR-700) against gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2012;56(9):4608-13
   PubMed Web of Science ®Google Scholar
• Available from: http://www.triusrx.com/trius-therapeutics-tedizolid-profile.php
   Google Scholar
• Kanafani ZA, Corey GR. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin Investig Drugs 2012;21(4):515-22
   PubMed Web of Science ®Google Scholar
• Available from: http://www.rib-x.com/pipeline/radezolid.php
   Google Scholar
• Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann NY Acad Sci 2011;1241:48-70; Review
   PubMed Web of Science ®Google Scholar
• Billeter M, Zervos MJ, Chen AY, et al. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis 2008;46:577-83
   PubMed Web of Science ®Google Scholar
• Jones RN, Stilwell MG, Sader HS, et al. Spectrum and potency of dalbavancin tested against 3322 gram-positive cocci isolated in the United States Surveillance Program (2004). Diagn Microbiol Infect Dis 2006;54:149-53
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Calic D, Schweizer F, et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010;70:859-86
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:1407-15
   PubMed Web of Science ®Google Scholar
• Durata Begins Dalbavancin Study Enrollment. Drug Discovery & Development - October 05, 2011
   Google Scholar
• Anderson DL. Oritavancin for skin infections. Drugs Today (Barc) 2008;44(8):563-75
   PubMed Web of Science ®Google Scholar
• Rubino CM, Van Wart SA, Bhavnani SM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother 2009;53:4422-8
   PubMed Web of Science ®Google Scholar
• Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 2012;54(Suppl 3):S203-13
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Milata J, McClure T, Wasilewski MM; SIMPLIFI Study Group. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011;55:3476-84
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Milata J, Fitzpatrick M, et al. Efficacy of oritavancin at single or infrequent doses for the treatment of complicated skin and skin structure infections [poster no. 1849]. 19th European Congress of Clinical Microbiology and Infectious Disease; 16 – 19 May 2009; Helsinki
   Google Scholar
• Available from: http://www.drugdevelopment-technology.com/projects/oritavancin/
   Google Scholar
• Available from: http://ir.themedicinescompany.com/phoenix.zhtml?c=122204&p=irol-newsArti
   Google Scholar
• Lauderdale T-L, Shiau Y-R, Lai J-F, et al. Comparative in vitro activities of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother 2010;54(3):1338-42
   PubMed Web of Science ®Google Scholar
• Available from: http://www.taigenbiotech.com.tw/pipeline.html
   Google Scholar
• Lawrence L, Pillar C, Saham D, Burak ES. In vitro activity of delafloxacin against European isolates of Staphylococcus aureus from skin and soft tissue, respiratory, urine and blood specimens. Poster in ESCMID; 2011
   Google Scholar
• Available from: http://www.rib-x.com/pipeline/delafloxacin.php
   Google Scholar
• Infectious Diseases Society of America. The 10 × 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081-3
   PubMed Web of Science ®Google Scholar